Trials / Conditions / Relapsed/Refractory Acute Myeloid Leukemia (AML)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

12 registered clinical trials studyying Relapsed/Refractory Acute Myeloid Leukemia (AML) — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients wi NCT05662904	German Cancer Research Center	Phase 1
Not Yet Recruiting	An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute M NCT07084584	Galecto Biotech AB	Phase 1 / Phase 2
Not Yet Recruiting	A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia NCT07441980	Institute of Hematology & Blood Diseases Hospital, China	Phase 1
Not Yet Recruiting	A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia NCT07233018	MEI HENG	Phase 1
Recruiting	Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cel NCT06869265	Peking University People's Hospital	Phase 2
Not Yet Recruiting	Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adul NCT06786299	First Affiliated Hospital of Zhejiang University	EARLY_Phase 1
Suspended	A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia NCT06709131	He Huang	Phase 1
Recruiting	A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies NCT06049667	Nanjing Chia-tai Tianqing Pharmaceutical	Phase 1
Recruiting	CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) NCT05143996	Cullinan Therapeutics Inc.	Phase 1
Terminated	Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leuke NCT03541369	Amgen	Phase 1
Terminated	CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia NCT03473457	Zhujiang Hospital	N/A
Completed	Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML NCT02626338	Arog Pharmaceuticals, Inc.	Phase 1 / Phase 2